Novo Nordisk Buys Time: A 27% Profit Jump, a New CFO, and a Guidance Call Deferred to February
Published on 11/05/2026 at 05:51 | Editorial boerse-global.de
Novo Nordisk delivered a third-quarter beat that sent its shares up 4.8% yesterday, but the more telling signal came from what management did not say. Chief executive Mike Doustdar declined to issue guidance for 2027, pushing that reckoning to the full-year results in February 2027. Between now and then, investors must decide whether the company's volume-led recovery can outrun the price cuts it has already scheduled for the U.S. market.
The headline numbers argue for optimism. Adjusted revenue for the third quarter of 2026 came in at DKK 79.2bn, a 4% increase at constant currencies. Adjusted operating profit grew far faster, climbing 27% at constant currencies to DKK 31.72bn — a margin performance that suggests the quarter was about more than top-line momentum. The Wegovy pill contributed DKK 5.39bn in revenue, and free cash flow exceeded DKK 28bn in the period.
Novo Nordisk also lifted its outlook for 2026, a move Reuters identified as a contributor to yesterday's share-price advance. The revised guidance now points to a range of -2% to +2% at constant currencies for both adjusted revenue and adjusted operating profit. That is a forecast which still permits contraction, a detail worth keeping in view before treating the quarter as the start of a durable upswing.
Jefferies Stays on the Sideline
Not everyone read the beat as a buying opportunity. Jefferies reaffirmed its "Hold" rating and DKK 275 price target yesterday, while noting that consensus estimates could rise because the improved outlook sits above prior expectations. The distinction matters: higher earnings and revenue forecasts are one thing, an upgraded recommendation is another. The broker's measured response stands in contrast to the market's more enthusiastic reception.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The growth itself deserves closer scrutiny than the headline percentage suggests. Roughly 60,000 weekly prescriptions flowed through the Medicare Bridge programme, meaning a meaningful slice of the volume gain came from a single access channel rather than from broad-based demand. Medicare coverage for seniors began in mid-2026, and next year it could contribute to sales across a full twelve-month period for the first time — a tailwind, but also a concentration risk if the rest of the market stays soft.
That caveat is not hypothetical. According to the company's U.S. chief, the American obesity-drug market outside Medicare was relatively stable between May and October. Strip out the programme's contribution and the picture looks considerably flatter.
The Price Test Arrives on January 1
Then there is the arithmetic of pricing. From January 1, 2027, Novo Nordisk will lower its U.S. list prices, with Ozempic expected to see an annual decline of 10–15%. More patients will therefore be needed simply to hold revenue steady, let alone grow it. The central question for the investment case is whether prescription volume can convert into revenue once those cuts take effect — a link the company has not yet made explicit.
On the pill specifically, the two sides of the argument diverge. Doustdar characterised signs of a plateau in prescriptions as seasonal and raised the possibility of a demand recovery after the holidays. Citi analysts, by contrast, suggested prescriptions may have already stabilised. A temporary pause and a permanently flatter trajectory carry very different implications, and the market will not know which it is facing until the data resolve the question.
A New Finance Chief Alongside the Numbers
Novo Nordisk paired its results with a leadership announcement. Luigi La Corte, currently finance chief at Galderma, has been appointed Executive Vice President and CFO. Karsten Munk Knudsen will leave the company at year-end after 27 years. The transition is a separate corporate development rather than a demonstrated driver of yesterday's share-price move — the stronger quarter and the prospect of revised analyst estimates remain the operative factors for how the stock is judged.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
What investors are really being asked to underwrite is the quality of the growth, not its quantity. If expanded access keeps converting into additional treatments and pill demand revives, the recent operating improvement could mark the beginning of a more durable recovery. If demand outside Medicare stalls or the prescription plateau proves permanent, the latest quarter will look less like a turning point and more like a pause.
The first real stress test begins with the U.S. list-price reductions at the turn of the year. The 2027 forecast, due alongside the full-year figures in February, is where Novo Nordisk must finally connect the dots between more patients, lower prices and expected financial performance. Until that outlook lands, a rising prescription count alone will not settle the case — only guidance that holds up under pricing pressure will.
Ad
Novo Nordisk Stock: New Analysis - 5 November
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
